Loading organizations...
§ Private Profile · 863 Mitten Road Suite 101 Urlingame, CA 94010
biotechnology company develops novel therapeutic molecules for biopharma partners, focused on small molecule therapeutics.
BlueLight Therapeutics is a South San Francisco, California-based biotechnology company that develops novel small molecule therapeutics against challenging drug targets using a proprietary structure-based discovery platform. The firm leverages Second Harmonic Generation technology to modulate target protein conformations, enabling structure-driven drug discovery for both its internal pipeline and external biopharmaceutical industry partnerships. Operating as a venture-backed enterprise funded by institutional investors, the business generates revenue through strategic collaborations across the broader biopharma sector. Formerly known as Biodesy, the organization rebranded to its current name in May 2020 while expanding its leadership team. During this transition, the company appointed Ariel G. Notcovich as an executive and brought on Mark Gallop as Chief Scientific Officer following his tenure as an Executive-in-Residence at 5AM Ventures. BlueLight Therapeutics was originally founded in 2013 by an undisclosed group of founders.
BlueLight Therapeutics has raised $45.0M across 3 funding rounds.
BlueLight Therapeutics has raised $45.0M in total across 3 funding rounds.
BlueLight Therapeutics has raised $45.0M across 3 funding rounds. Most recently, it raised $20.0M Series C in September 2018.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 10, 2018 | $20M Series C | Monica Beam | Mark Gallop, Mitchell Mutz | Announced |
| Jan 1, 2016 | $10M Series B | 5AM Ventures, Pfizer, Roche | Pfizer Venture Investments, RED Tree Venture Capital | Announced |
| Oct 1, 2013 | $15M Series A | — | 5AM Ventures, Pfizer Venture Investments, RED Tree Venture Capital, Bill Burkoth, Roche | Announced |
BlueLight Therapeutics has raised $45.0M in total across 3 funding rounds.
BlueLight Therapeutics's investors include Monica Beam, Mark Gallop, Mitchell Mutz, 5AM Ventures, Pfizer, Roche, Pfizer Venture Investments, Red Tree Venture Capital, Bill Burkoth.
BlueLight Therapeutics is a biotechnology company specializing in structure-driven drug discovery, developing small molecule therapeutics that modulate the conformation of challenging drug targets using a proprietary platform based on Second Harmonic Generation (SHG) technology.[1][2] It serves the biopharmaceutical industry through partnerships to advance novel therapeutics, initially focusing on oncology by targeting conformationally regulated, difficult-to-drug proteins key to disease progression.[1][2] The platform enables real-time, high-throughput measurement of biomolecular conformational changes, bridging target-based and phenotypic screening to identify chemical matter overlooked by traditional methods, with a pipeline aimed at serious diseases.[1]
Formerly Biodesy, the company rebranded in 2020 to emphasize its shift toward therapeutic development, backed by experienced leadership and investors.[1][2][5]
BlueLight Therapeutics traces its roots to 2013, when it was founded as Biodesy in South San Francisco, California, initially as a life science instrumentation company.[1][5] The idea emerged from advanced biophysical technologies, including SHG for label-free analysis of molecular interactions, building on founder Ariel G. Notcovich's background in physics and entrepreneurship.[1][2] Notcovich, who earned his graduate studies at the Technion-Israel Institute of Technology, founded ProteOptics (acquired by Bio-Rad Laboratories), where he advanced imaging and protein analysis tools, later leading R&D at Bio-Rad.[2]
A pivotal moment came in May 2020, when Biodesy rebranded to BlueLight Therapeutics and appointed Mark Gallop, PhD, as Chief Scientific Officer, signaling a strategic evolution from instrumentation to small molecule therapeutics development.[1][2] Gallop, with prior roles as founding CSO at Nurix and co-founder of XenoPort (which yielded the FDA-approved Horizant), brought deep drug discovery expertise from Affymax and 5AM Ventures.[2]
BlueLight rides the wave of precision drug discovery, where biophysical platforms address "undruggable" targets amid rising demand for novel oncology therapies amid stagnant traditional screening success rates.[1][2] Timing aligns with advances in structural biology (e.g., cryo-EM, AI-driven design), amplifying SHG's conformational insights to accelerate hit-to-lead transitions in a market favoring modalities like targeted protein degraders.[2] Favorable forces include biopharma's push for high-value targets in immuno-oncology and neurodegeneration, plus venture interest in platform-enabled pipelines.[1][2] BlueLight influences the ecosystem by partnering with industry leaders, potentially licensing tech or spinning out candidates, contributing to a shift from empirical to data-rich discovery.[1]
BlueLight is poised to advance its oncology-focused pipeline, with SHG platform expansions likely targeting neurodegeneration or immunology as conformational modulators gain traction.[1][2] Trends like AI integration for structure prediction and combo therapies with degraders will shape its path, potentially yielding IND candidates or partnerships by late 2020s.[2] Its influence may grow through proof-of-concept data, attracting big pharma deals and solidifying its niche in next-gen biophysics-driven biotech. This positions BlueLight as a key player bridging tools and therapeutics in an era demanding breakthroughs on tough targets.[1]